Donepezil and Memantine for Moderate-to-Severe Alzheimer's Disease | Zendy

Robert Howard | Zendy; Rupert McShane | Zendy; James Lindesay | Zendy; Craig Ritchie | Zendy; Ashley Baldwin | Zendy; Robert Barber | Zendy; Alistair Burns | Zendy; Tom Dening | Zendy; David M. Findlay | Zendy; Clive Holmes | Zendy; Alan Hughes | Zendy; Robin Jacoby | Zendy; Rob Jones | Zendy; Roy Jones | Zendy; Ian G. McKeith | Zendy; Ajay Macharouthu | Zendy; John T. O’Brien | Zendy; Peter Passmore | Zendy; Bart Sheehan | Zendy; Edmund Juszczak | Zendy; Cornelius Katona | Zendy; Robert K. Hills | Zendy; Martín Knapp | Zendy; Clive Ballard | Zendy; Richard G. Brown | Zendy; Sube Banerjee | Zendy; Caroline Onions | Zendy; Mary Griffin | Zendy; Jessica Adams | Zendy; Richard Gray | Zendy; Tony Johnson | Zendy; Peter Bentham | Zendy; Patrick Phillips | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Donepezil and Memantine for Moderate-to-Severe Alzheimer's Disease

Author(s) -

Robert Howard,

Rupert McShane,

James Lindesay,

Craig Ritchie,

Ashley Baldwin,

Robert Barber,

Alistair Burns,

Tom Dening,

David M. Findlay,

Clive Holmes,

Alan Hughes,

Robin Jacoby,

Rob Jones,

Roy Jones,

Ian G. McKeith,

Ajay Macharouthu,

John T. O’Brien,

Peter Passmore,

Bart Sheehan,

Edmund Juszczak,

Cornelius Katona,

Robert K. Hills,

Martín Knapp,

Clive Ballard,

Richard G. Brown,

Sube Banerjee,

Caroline Onions,

Mary Griffin,

Jessica Adams,

Richard Gray,

Tony Johnson,

Peter Bentham,

Patrick Phillips

Publication year - 2012

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1106668

Subject(s) - donepezil , memantine , medicine , placebo , alzheimer's disease , dementia , disease , pathology , alternative medicine

Clinical trials have shown the benefits of cholinesterase inhibitors for the treatment of mild-to-moderate Alzheimer's disease. It is not known whether treatment benefits continue after the progression to moderate-to-severe disease.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom

About

About Careers Publisher Partners Contact Us Get Organisational Trial or Quote

Learn

FAQs Blog Terms of Use Privacy Policy

Download the Zendy App

Address

About

Learn

Download the Zendy App

Discover

Explore